Crossref
A production route for lead-212 for Targeted Alpha Therapy; Using the UK’s nuclear legacy for cancer treatment
Nuclear Future · 09.07.2026 · 22 (4)
DOI: 10.63198/nuclearfuture22448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuclear Future, online erschienen am 10.07.2026. Verfasst von Howard Greenwood und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Greenwood, H., Ree, S., Tinsley, T., Roberts, R., Murray, L., & Dinsley, J. (2026). A production route for lead-212 for Targeted Alpha Therapy; Using the UK’s nuclear legacy for cancer treatment. Nuclear Future, 22(4). https://doi.org/10.63198/nuclearfuture22448
Vancouver
Greenwood H, Ree S, Tinsley T, Roberts R, Murray L, Dinsley J. A production route for lead-212 for Targeted Alpha Therapy; Using the UK’s nuclear legacy for cancer treatment. Nuclear Future. 2026;22(4). doi:10.63198/nuclearfuture22448
BibTeX
@article{Greenwood2026,
author = {Greenwood, Howard and Ree, Samantha and Tinsley, Tim and Roberts, Rachel and Murray, Laura and Dinsley, James},
title = {A production route for lead-212 for Targeted Alpha Therapy; Using the UK’s nuclear legacy for cancer treatment},
journal = {Nuclear Future},
year = {2026},
volume = {22},
number = {4},
doi = {10.63198/nuclearfuture22448}
}
EUVIMED